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The lysosome has a key role in the presentation of lipid antigens by CD1 molecules.
While defects in lipid antigen presentation and in invariant Natural Killer T (iNKT) cell
response were detected in several mouse models of lysosomal storage diseases (LSD),
the impact of lysosomal engorgement in human lipid antigen presentation is poorly
characterized. Here, we analyzed the capacity of monocyte-derived dendritic cells
(Mo-DCs) from Fabry, Gaucher, Niemann Pick type C andMucopolysaccharidosis type VI
disease patients to present exogenous antigens to lipid-specific T cells. The CD1b- and
CD1d-restricted presentation of lipid antigens by Mo-DCs revealed an ability of LSD
patients to induce CD1-restricted T cell responses within the control range. Similarly,
freshly isolated monocytes from Fabry and Gaucher disease patients had a normal ability
to present α-Galactosylceramide (α-GalCer) antigen by CD1d. Gaucher disease patients’
monocytes had an increased capacity to present α-Gal-(1-2)-αGalCer, an antigen that
needs internalization and processing to become antigenic. In summary, our results show
that Fabry, Gaucher, Niemann Pick type C, and Mucopolysaccharidosis type VI disease
patients do not present a decreased capacity to present CD1d-restricted lipid antigens.
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These observations are in contrast to what was observed in mouse models of LSD. The
percentage of total iNKT cells in the peripheral blood of these patients is also similar
to control individuals. In addition, we show that the presentation of exogenous lipids
that directly bind CD1b, the human CD1 isoform with an intracellular trafficking to the
lysosome, is normal in these patients.
Keywords: lipid antigen presentation, CD1b, CD1d, dendritic cells, monocytes, lysosomal storage diseases,
natural killer T cells
INTRODUCTION
T lymphocytes can recognize lipid antigens presented by almost
nonpolymorphic CD1 antigen-presenting molecules. In humans,
CD1a, CD1b, CD1c, and CD1d are capable of presenting lipid
antigens to T cells, while in mice only CD1d isoform is expressed.
After synthesis, CD1 molecules traffic to the cell surface and
are then internalized through the endocytic pathway. Along this
recycling route, each CD1 isoform preferentially localizes in a
different intracellular compartment, allowing them to encounter
distinct lipid antigens (1). CD1a molecules mainly localize in
early endosomes and possess the smallest groove, binding small
lipids. CD1b traffics to lysosomes and is the isoform capable of
binding larger lipids. CD1c and human CD1d have intermediate
binding grooves and follow similar trafficking pathways, being
localized in late endosomes. The trafficking pathway of mouse
CD1d is similar to that used by human CD1b (2).
CD1-restricted T cells play important functions in the context
of infection, immune response against tumors and autoimmunity
(3). These cells can be classified by their recognition of antigens
presented by group 1 CD1molecules (CD1a, CD1b, andCD1c) or
by CD1d. Broadly, group 1 CD1-restricted T cells are polyclonal
and expand after antigen recognition in the periphery. CD1a-
restricted T cells are among the most common self-reactive T
cells in peripheral blood (4, 5), being abundant in skin where
they are activated by Langerhans cells (4). CD1b-restricted
T cells might recognize either microbial or self-lipids (6–10)
although circulating self-reactive CD1b-restricted T cells have
lower frequency (4, 5). Less consensual is the frequency of CD1c-
restricted T cells (4, 5), which can be explained by a direct
contact of the TCR with CD1c instead of the loaded lipids
(11). Finally, CD1d-restricted T cells or Natural Killer T (NKT)
cells, as they are also known because of their expression of
NK and T cells surface markers, are divided into two subsets.
Type I NKT or invariant NKT (iNKT) cells are characterized
by the expression of a semi-invariant TCR (Vα24Jα18Vβ11
in humans and Vα14Jα18 paired with a limited repertoire of
Vβ chains in mice) that recognizes the prototypic antigen α-
galactosylceramide (α-GalCer). On the other hand, type II NKT
Abbreviations: α-Gal A, α-Galactosidase A; α-GalCer, α-Galactosylceramide;
APC, antigen presenting cell; BSA, bovine serum albumin; CBE, conduritol
B epoxide; DGJ, deoxinojirimycin; ERT, enzyme replacement therapy; Gb3,
globotriaosylceramide; GCase, β-Glucosidase; GlcCer, glucosylceramide; GM-CSF,
granulocyte-macrophage colony stimulating factor; iNKT, invariant natural killer
T; LSD, lysosomal storage diseases; Mo-DCs, monocyte-derived dendritic cells;
NPC, Niemann-Pick type C; PE, phosphatidylethanolamine.
cells express variable TCRs. While iNKT cells respond rapidly
to both innate signals and TCR engagement producing large
amounts of cytokines, some type II NKT cells display adaptive-
like immune functions (5, 12).
Besides being the preferential intracellular compartment for
CD1b and mouse CD1d localization, the lysosome contains
hydrolytic enzymes and lipid-transfer proteins that process
lipid antigens and assist the loading of lipids onto CD1
molecules, respectively (13–20). In addition, the low pH in
this compartment induces relaxation of the CD1d structure,
facilitating the loading of lipids (21). Indeed, the importance of
the lysosome in lipid antigen presentation by mouse CD1d is
reinforced by the defects described in mouse models of lysosomal
storage diseases (LSDs) (22). LSDs are a group of individually rare
inheritedmetabolic diseases characterized by the accumulation of
specificmacromolecules in the lysosome, including lipids, usually
as a result of a deficiency in a lysosomal enzyme. There is no
effective treatment for most LSDs. However, for some specific
LSDs, enzyme replacement and/or substrate reduction therapies
have been developed (23, 24). Lipid antigen presentation by
CD1d is impaired in mouse models of several LSD including
Sandhoff (25, 26), Niemann-Pick C (NPC) (16, 26–28), GM1
gangliosidosis (26, 28), and Fabry disease (26, 29). The alteration
in lipid antigen presentation is accompanied by a defect in the
percentage of both thymic and peripheral iNKT cells (16, 26–30).
However, in NPC disease (31), Fabry disease (32), and Gaucher
disease (33) patients’ blood, no differences were observed in
the frequency of total iNKT cells. Nevertheless, Fabry patients
showed a reduction in the CD4+ and an increase in the double
negative (DN) iNKT populations (32).
The abnormal accumulation of material in the lysosome/late
endosomes of LSD patients is a key feature in LSD. However,
there are several other cellular alterations described in the
context of these diseases. In fact, impairment in endolysosomal
trafficking (34, 35) has been described in several LSDs, namely
NPC disease. In this regard, such impairment results in a greater
accumulation of lipids in the late endosome (36). Moreover,
defects in autophagy and lipid trafficking have also been reported
(34, 37, 38) and, in Gaucher disease, an increase in lysosomal pH
has been described (39), most likely impairing the relaxation of
CD1 molecules’ structure, thus hindering the loading of lipids in
these molecules. Altogether, these cellular alterations may affect
lipid antigen presentation by human CD1molecules, particularly
CD1b, which recycles through the lysosome (40).
However, studies of lipid antigen presentation in LSD patients
are scarce; to date, the analysis of lipid antigen presentation in
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LSD patients is restricted to NPC disease where only CD1d-
mediated presentation was studied using EBV transformed B
cell lines as antigen presenting cells (APCs) (31). Herein, lipid
antigen presentation by human CD1b and CD1d was studied
in the context of four of the most common LSDs: Fabry,
Gaucher, NPC, and MPS-VI diseases. These diseases represent
LSD with distinct symptomatology and are characterized by the
accumulation of different types of molecules in the lysosomes
(Table 1). Gaucher and Fabry diseases are sphingolipidoses
caused, respectively, by pathogenic mutations in GBA [encoding
β-Glucosidase (GCase)] and GLA [encoding α-galactosidase
A (α-Gal A)] genes (Table 1) and present as multisystemic
disorders. Gaucher disease involves the visceral organs, bone
marrow, and bone in almost all affected patients, whereas in
Fabry disease involvement of the heart, kidney, and brain are
the main sources of morbidity and premature death (41, 42).
NPC disease is caused by defective transport of cholesterol
(due to NPC1 and NPC2 genes’ defects) with sequestration of
unesterified cholesterol in lysosomes and late endosomes, and
is clinically heterogeneous, mainly affecting the visceral organs
(liver, spleen, and lungs) and the central nervous system (43).
MPS VI is caused by arylsufatase B (ASB) enzyme deficiency and
leads to the accumulation of dermatan sulfate and chondroitin
sulfate (Table 1), which manifests as a multisystemic disorder
affecting mainly the skeleton (44). The contribution of Type II
NKT cells in the development of chronic B-cell activation and
gammopathy in Gaucher disease has been proposed (33). For
the other LSD, the contribution of CD1-restricted T cells to the
clinical manifestation is not well defined. However, we could
envision that they may be involved in LSD-associated chronic
inflammation (34).
In contrast to the data obtained in mice, no defects in lipid
antigen presentation by CD1b or CD1d were observed in patients
of this study, results that are also supported by the determination
of normal frequencies of peripheral blood iNKT cells.
MATERIALS AND METHODS
Biological Samples
Antigen presentation assays included 8 Fabry (only males),
16 Gaucher, 8 NPC (all with mutations in the NPC1 gene),
TABLE 1 | Characteristics of lysosomal storage diseases studied.
Disease Protein defect Material stored
Fabry α-Galactosidase A
(α-Gal A)
Globotriaosylceramide
(Gb3)
Gaucher β-Glucosidase
(GCase)
Glucosylceramide
(GlcCer),
Glucosylsphingosine
(GlcSph)
Niemann-Pick
disease (NPC)
Niemann-Pick C1
or C2
(NPC1/NPC2)
Unesterified
cholesterol,
Sphingolipids
Mucopolysaccharisodis
type VI (MPS-VI)
Arylsulfatase B
(ASB)
Dermatan sulfate,
Chondroitin sulfate
7 MPS-VI disease patients, and 52 healthy blood donors (all
adults). Four Fabry and two Gaucher patients were not
undergoing enzyme replacement therapy. The primary etiology
and nature of the stored material for the four LSDs studied are
depicted in Table 1. Table 2 indicates patient details and the
correspondent codes used for their identification in the antigen
presentation assays.
Studies of iNKT cell frequencies included 15 Fabry (8 males,
7 females, all adults), 19 Gaucher (8 males−1 pediatric, 11
females−3 pediatrics), 9 NPC (all with mutations in the NPC1
TABLE 2 | Patients analyzed in antigen presentation assays.
Disease Code Age range* ERT/SRT
Fabry 1F 51–55 Yes
2F 36–40 Yes
3F 61–65 Yes
4F 51–55 Yes
5F 46–50 No
6F 36–40 No
7F 16–20 No
8F 21–25 No
Gaucher 1G 1–5 Yes
2G 11–15 Yes
3G 26–30 Yes
4G 11–15 Yes
5G 51–55 No
6G 46–50 Yes
7G 76–80 Yes
8G 66–70 Yes
9G 26–30 No
10G 36–40 Yes
11G 71–75 Yes
12G 71–75 Yes
13G 60–65 Yes
14G 6–10 Yes
15G 21–25 Yes
16G 21–25 Yes
NPC 1N 1–5 Yes
2N 16–20 Yes
3N 16–20 Yes
4N 6–10 Yes
5N 21–25 Yes
6N 26–30 Yes
7N 31–35 Yes
8N 11–15 Yes
MPS-VI 1M 16–20 Yes
2M 16–20 Yes
3M 26–30 Yes
4M 11–15 Yes
5M 16–20 Yes
6M 16–20 Yes
7M 5–10 Yes
*Patient age was within this interval at the moment of the study.
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gene, 6 males−2 pediatrics, 3 females−1 pediatric), 13 MPS-VI
disease patients (6 males−2 pediatrics, 7 females−3 pediatrics),
and 92 healthy blood donors (77 adults−37males and 40 females,
15 children−12 males and 3 females). Patients and controls ≥16
years old were considered as adults.
Written informed consent was obtained from all patients
enrolled in the study in accordance with the Helsinki declaration.
The study was approved by local ethical committees (from
the hospitals where patients and controls were recruited)
and by the national commission of data protection. Patients
were recruited from São João Hospital, Porto—Portugal; Santo
António Hospital, Porto—Portugal; Santa Maria Hospital,
Lisbon—Portugal; Senhora da Oliveira Hospital, Guimarães—
Portugal; Pediatric Coimbra Hospital, Coimbra—Portugal; Sant
Joan de Déu Hospital, Barcelona—Spain; Federico II University
Hospital, Naples—Italy; and University Children’s Hospital,
Mainz—Germany. All but one of the NPC patients were
under substrate reduction therapy (SRT). Most of the Fabry,
Gaucher and MPS-VI disease patients analyzed were under
enzyme replacement therapy (ERT). In Table 2; Figure 6, and
Supplementary Figure 1 it is indicated whether the patients
are under treatment or not. Fabry and Gaucher patients
received ERT by infusion every 2 weeks, while MPS VI
patients were treated intravenously with ERT weekly. NPC
patients received oral daily substrate reduction therapy. Blood
samples from Fabry, Gaucher, and MPS-VI disease patients
were always collected before treatment infusion to minimize
the putative effect of treatments in the analyzed cells. The
adult control subject population was composed of healthy
blood donors from the Instituto Português do Sangue, Porto—
Portugal, or from the Immuno-hemotherapy department of
São João Hospital. Control pediatric subjects were recruited
among children undergoing orthopedic surgery at São João
Hospital, without infections, underlying chronic illness, or
taking medication.
Peripheral Blood Mononuclear Cells
Isolation (PBMCs), Monocytes Purification,
and Mo-DCs Generation
PBMCs were separated by Histopaque-1077 R© (Sigma-Aldrich,
St. Louis, MO, USA) density centrifugation following the
manufacturer’s instructions. Monocytes were isolated by positive
selection with anti-CD14 magnetic beads using the MACS cell
separation system (Miltenyi Biotec, Cologne, Germany).
CD14+ cells were used after purification (monocytes) or to
promote differentiation in dendritic cells by plating them at 106
cells/mL in RPMI 10% iFBS supplemented with 50 ng/mL of IL-
4 and GM-CSF (ImmunoTools, Friesoythe, Germany). After 7
days, monocyte-derived dendritic cells (Mo-DCs) were collected
and used for lipid antigen presentation assays.
Flow Cytometry
Monocyte purity, proper Mo-DC differentiation and the basal
state of activation of both cells were assessed by flow cytometry
using the following anti-human monoclonal antibodies: CD14
(M5E2, Biolegend, San Diego, CA, USA), CD1b (SN13,
Biolegend), CD1d (51.1, Biolegend), CD11c (3.9, eBioscience),
CD80 (2D10, Biolegend), HLA-DR (LN3, eBioscience).
iNKT and T cell determinations were performed in total
PBMCs or in CD14− fractions, using CD1d-PBS57 tetramers
(NIH Tetramer Core Facility, Emory University, Atlanta, GA,
USA) and the following anti-human monoclonal antibodies:
CD3 (OKT3, eBioscience), CD4 (OKT4, Biolegend), and CD8
(RPA-T8, eBioscience). The purity of T cell clones VM-D5
and JS63 was assessed by using CD1d-PBS57 tetramers (NIH
Tetramer Core Facility, Emory University, Atlanta, GA, USA)
together with anti-human CD3 (OKT3, eBioscience) monoclonal
antibody. The purity of T cell clones s33d, GG33A, and DS1C9b
was assessed by using anti-human TCR Vβ13.1 (IMMV222),
Vβ18 (BA62.6), and Vβ7.1 (ZOE), monoclonal antibodies from
Immunotec (Immunotec Research Inc, Canada). Cells were
acquired in a FACS Canto II (BD Biosciences, San Diego, CA,
USA) using the BD FACSDivaTM software (BD Biosciences). Data
analysis was performed with FlowJo R© v10 (FlowJo LLC, Ashland,
OR, USA).
Generation of Fabry and Gaucher Disease
in vitro Models
Generation of the Fabry and Gaucher disease in vitro cell
models was adapted from previously described protocols
(45, 46). To induce Globotriaosylceramide (Gb3) accumulation,
CD1-transfected C1R cells were cultured for 72 h in the
presence of 1mM deoxynojirimycin (DGJ, Sigma-Aldrich)
alone or together with 10µM Gb3 (Matreya, LLC, Pleasant
Gap, PA, USA) in complex with fatty acid-free bovine
serum albumin (BSA) (Sigma-Aldrich). Glucosylceramide
(GlcCer) accumulation in CD1-transfected C1R cells
was achieved by a 72 h culture with 1mM conduritol B
epoxide (CBE, Sigma-Aldrich). Treated and untreated cells
were collected and used for lipid antigen presentation
assays or pelletized. Pellets were analyzed by Thin-layer
chromatography (TLC).
Thin-Layer Chromatography
Thin-layer chromatography of neutral lipids from CD1-
transfected C1R cell pellets was performed as described
(47). To overcome plate loading differences, the intensity of
GlcCer and Gb3 bands was divided by the intensity of the
Sph/Gb4 band. The lipid standards used were the following:
glucosylceramide (GlcCer); phosphatildylethanolamine (PE);
lactosylceramide (LacCer) and sphingomyelin (Sph) from
Sigma-Aldrich; globotriaosylceramide (Gb3) from Nacalai
Tesque Inc.; ganglioside GM1 (Cer4) from Calbiochem; and
globotetrahexosylceramide (Gb4) from Matreya.
T Cell Clone/iNKT Cell Line Culture
and Re-stimulation
The maintenance of T cell clones and of the iNKT cell line
was performed as previously described (48). The following T
cell clones were used in the assays: DS1C9b (CD1b-restricted,
sulfatide-specific) (49); GG33A (CD1b-restricted, GM1-specific)
(48); JS63 (CD1d-restricted, α-GalCer-specific) (50); VM-D5
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(CD1d-restricted, α-GalCer-specific) (50) and s33d (CD1d-
restricted, sulfatide-specific) (50). An iNKT cell line (51) was
also used.
Lipid Antigen Presentation Assays
Monocytes, Mo-DCs or CD1-transfected C1R cells were
cultured with sulfatide (30–0.04µg/mL, Sigma-Aldrich),
GM1 (50–0.07µg/mL, Sigma-Aldrich), α-Galactosylceramide
(α-GalCer) (at 50 ng/mL or 50–3.12 ng/mL, Avanti polar
lipids, Alabaster, AL, USA) or α-Gal-(1-2)-αGalCer (300–
50 ng/mL). Lipids, with the exception of α-GalCer, were
first dissolved in methanol or PBS 0.5% Tween 20 and then
diluted in non-supplemented RPMI to have a maximum of
1% vehicle in culture. α-GalCer was resuspended in PBS
and directly diluted in non-supplemented RPMI. After 4 h,
an iNKT cell line or T cell clones were added and 40 h
later, supernatants were collected for cytokine production
determination by ELISA. The following antibody pairs from
Biolegend were used: purified anti-human GM-CSF (BVD2-
23B6) and biotinylated anti-human GM-CSF (BVD2-21C11);
purified anti-human IL-4 (8D4-8) and biotinylated anti-human
IL-4 (MP4-25D2).
Statistics
Data distribution of the frequencies of iNKT cells (total, CD4+,
CD8+, DN) and T cells (total, CD4+, CD8+) from adult and child
healthy controls was assessed using the D’Agostino & Pearson
test. Then, an unpaired t-test (normal distribution) or a Mann-
Whitney test (non-normal distribution) was used to compare
adult and child healthy control populations. As no significant
differences were observed (results not shown), data from adults
and children were pooled.
To compare the frequencies of iNKT cells (total, CD4+,
CD8+, DN) and T cells (total, CD4+, CD8+) from LSD patients
and healthy controls, data normality was first checked using the
D’Agostino & Pearson test. When all the populations studied
passed the normality test, an ordinary one-way ANOVA was
used to compare each group of patients with controls. When
the populations analyzed did not pass the normality test, the
Kruskal-Wallis test was used. P-values lower than 0.05 were
considered significant.
Statistical analysis of lipid antigen presentation assays was
performed by comparing the amount of cytokine produced in
the coculture of APC with T cells between LSD patients and
control subjects. A single concentration of antigen was used
for this purpose. Data normality was first checked using the
Shapiro–Wilk test. Then, an unpaired t-test (normal distribution)
or a Mann-Whitney test (non-normal distribution) was used
to compare the two groups. P-values lower than 0.05 were
considered significant. Along with the comparison of the raw
data, and due to the inter-experimental variation, comparison
was also done after normalization of the values of cytokine
production for each independent experiment. The values of
cytokine production were relativized considering 100 as the
highest cytokine production value within each experiment for the
chosen antigen concentration. All the analyses were performed
using GraphPad Prism software v7.04 (GraphPad Software Inc.,
CA, USA).
RESULTS
Mo-DCs From Fabry, Gaucher, NPC and
MPS-VI Disease Patients Do Present
Antigens by CD1b
in vitro differentiation of monocytes to dendritic cells (Mo-DCs)
is accompanied by an increase in the expression of CD1b (52).
To study antigen presentation by CD1b, the capacity of Mo-
DCs from Fabry, Gaucher, NPC (with mutations in NPC1) and
MPS-VI disease patients to present lipids by CD1b was analyzed
and compared with that of healthy controls. The expression of
CD80 and CD1b on the surface of Mo-DCs from patients and
controls was assessed after the differentiation process and prior
to the experiments. Mo-DCs from LSD patients had similar levels
of CD1b and CD80 cell surface expression to those of control
subjects (Supplementary Table 1).
Two previously described CD1b restricted T cell clones were
used: the GG33A T cell clone, specific for GM1 (48), and the
DS1C9b T cell clone, sulfatide specific (49). The GG33A T cell
clone carries the Vβ18 TCR chain while the DS1C9b T cell clone
expresses the Vβ7.1 TCR chain (personal communication from
Lucia Mori and Gennaro de Libero who produced the T cell
clones). The identity of the T cell clones was confirmed by flow
cytometry (Supplementary Figure 2).
Mo-DCs from Fabry (Figure 1A), Gaucher (Figure 1B), NPC
(Figure 1C), and MPS-VI (Figure 1D) disease patients were
capable of presenting the exogenously added antigen GM1 to the
CD1b-restricted T cell clone GG33A (Supplementary Figure 3).
Curiously, Mo-DCs from NPC disease patients seem to
have a higher presentation capacity of the antigen GM1
when comparing with control subjects. This difference was
statistically significant (P = 0.0041) for the normalized
values of cytokine production in the presence of 5µg/mL
of GM1 (Supplementary Figure 3A). Regardless of the higher
presentation capacity observed in NPC patients to present GM1
through CD1b, the same was not observed using the sulfatide-
specific CD1b-restricted DS1C9b T cell clone (Figure 1F
and Supplementary Figure 3B). Sulfatide presentation through
CD1b was also analyzed in Fabry patients’ Mo-DCs, and
a small decrease in the capacity to activate the DS1C9b
clone was observed (Figure 1E) when considering one of
the tested concentrations (1µg/mL of sulfatide, P = 0.0456)
(Supplementary Figure 3B).
To overcome the high degree of variability observed when
testing patients as well as control subjects, and to assure that
lipid storage was indeed occurring, we used cellular models
of Fabry (45) and Gaucher (46) diseases. C1R cells expressing
CD1b were treated with DGJ, an inhibitor of α-galactosidase
A (α-Gal A) (the enzyme deficient in Fabry disease) alone or
together with Gb3 (the main storage material of Fabry disease)
complexed with BSA, or with CBE, an inhibitor of the enzyme β-
glucosidase (GCase) (deficient in Gaucher disease). TLC analyses
confirmed that simultaneous treatment with DGJ and Gb3:BSA
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FIGURE 1 | CD1b-restricted lipid antigen presentation by Mo-DCs from Fabry, Gaucher, NPC and MPS-VI disease patients. Mo-DCs from Fabry (A), Gaucher (B),
NPC (C), and MPS-VI (D) disease patients and control subjects were loaded with graded doses of GM1 and co-cultured with the CD1b-restricted T cell clone
GG33A. Mo-DCs from Fabry (E) and NPC (F) disease patients and control subjects were loaded with graded doses of sulfatide and co-cultured with the
CD1b-restricted T cell clone DS1C9b. T cell response was analyzed by measuring GM-CSF release to the supernatant by ELISA. Patients are represented with filled
symbols and control subjects with open symbols. Each symbol represents mean ± SD of duplicates for the same individual at the indicated antigen concentration.
Each graph corresponds to an independent experiment.
induced Gb3 accumulation (Supplementary Figure 4A) and that
culture with CBE induced glucosylceramide (GlcCer) storage
(Supplementary Figure 4B). These cells were then used as APCs
in antigen presentation assays. No differences were observed
when cells accumulating Gb3 (Figure 2A) or GlcCer (Figure 2B)
were compared with untreated cells for their capacity to present
the antigens by CD1b.
In conclusion, no major differences were found in CD1b-
restricted presentation of GM1 or sulfatide antigens to specific
T cell clones between healthy subjects and LSD patients.
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FIGURE 2 | CD1b-restricted lipid antigen presentation by in vitro cell models
of Fabry and Gaucher diseases. (A) Fabry disease in vitro cell model:
CD1b-transfected C1R cells were treated with DGJ 1mM + Gb3:BSA (filled
symbols) or remained untreated (empty symbols). (B) Gaucher disease in vitro
cell model: CD1b-transfected C1R cells were treated with CBE (filled symbols)
or remained untreated (empty symbols). Then, C1R cells were loaded with
graded doses of GM1 or sulfatide and co-cultured with the CD1b-restricted T
cell clone GG33A or DS1C9b, respectively. T cell response was analyzed by
measuring GM-CSF release to the supernatant by ELISA. Each symbol
represents mean ± SD of duplicates for the same individual at the indicated
antigen concentration. One representative experiment out of at least
two is shown.
Mo-DCs From Fabry, Gaucher, NPC and
MPS-VI Disease Patients and Fabry and
Gaucher Fresh Monocytes, Do Present
Antigens by CD1d
Several LSD animal models demonstrated defects in CD1d-
mediated lipid antigen presentation to iNKT cells, including
Fabry and NPC disease mouse models (16, 26–29). Type II NKT
cells also constitute an important part of CD1d-restricted T cells
in humans (53). We analyzed the capacity of Mo-DCs from
Fabry, Gaucher, NPC, and MPS-VI disease patients to activate
the iNKT cell clone JS63 in response to α-GalCer and the type II
NKT cell clone s33d (50) in response to sulfatide by measuring
cytokine production by ELISA. The s33d T cell clone carries
the TCR Vβ13.1 (50), which was used to confirm the identity of
the s33d T cells by flow cytometry (Supplementary Figure 2).
Analysis of CD1d and CD80 expression by Mo-DCs revealed no
significant differences between control subjects and LSD patients
(Supplementary Table 1). In Supplementary Figure 5 we
analyzed cytokine production in response to antigen stimulation
in Mo-DCs-iNKT cell cocultures. Cytokine production was
also measured in parallel cultures of Mo-DCs only and Mo-
DCs plus lipid antigen without iNKT cells. As expected,
iNKT cells responded to α-GalCer loaded Mo-DCs with high
production of GM-CSF. However, Mo-DCs cultured alone
were also able to produce some GM-CSF, with or without lipid
antigen stimulation.
α-GalCer presentation by Fabry, Gaucher, NPC, and MPS-
VI Mo-DCs was successful, although some variation in the
degree of activation could be observed among both control
subjects and LSD patients (Figures 3A–D). The presentation
of sulfatide to type II NKT cells by Mo-DCs from Fabry and
Gaucher patients was also studied (Figures 3E,F). No statistically
significant differences were observed in the capacity of Mo-
DCs from patients and controls to present α-GalCer and
sulfatide to iNKT cells and type II NKT cells, respectively
(Supplementary Figure 6).
Modifications of the cellular lipid content and in CD1d
expression occur during the process of in vitroDC differentiation
from monocytes (52). Therefore, Mo-DCs might not be
representative of the lipid antigen presentation occurring in vivo
in patients. To overcome this issue, we used fresh monocytes
from Fabry and Gaucher patients in addition to control subjects
as APC in activation assays with an iNKT cell line (51) using
α-GalCer (Fabry and Gaucher) and α-Gal-(1-2)-αGalCer
(Gaucher) as antigens. α-Gal-(1-2)-αGalCer only becomes
antigenic after cleavage in the lysosome by α-Gal A, the enzyme
deficient in Fabry disease patients, meaning that the loading into
CD1d preferentially happens inside the cell. Monocytes from
LSD patients had similar levels of CD1d and CD80 cell surface
expression to those of control subjects (Supplementary Table 2).
Similar to what was observed when Mo-DCs were used, a
variation in the T cell response was observed between subjects
(Figure 4). Nevertheless, monocytes from Fabry (Figure 4A) and
Gaucher patients (Figure 4B) were able to activate the iNKT cell
line within the range of control monocytes when stimulated with
α-GalCer. Monocytes from Gaucher disease patients (Figure 4B)
have a higher capacity of α-Gal-(1-2)-αGalCer presentation
when compared with control subjects. This difference was
statistically significant (P = 0.005) for the normalized values of
cytokine production in the presence of 50 ng/mL of the antigen
(Supplementary Figure 7).
We confirm the results of α-GalCer presentation, in a system
that eliminates individual donor variability, and we tested the
capacity of Gb3- and GlcCer-loaded C1R cells expressing CD1d
to present α-GalCer by CD1d. We found that both Fabry
(Figure 5A) and Gaucher (Figure 5B) in vitro APC models
had similar abilities to activate iNKT cells, in comparison with
unloaded cells. Thus, APCs from Fabry, Gaucher, NPC, and
MPS-VI disease patients are capable of presenting lipid antigens
that bind CD1d.
Fabry, Gaucher, NPC and MPS-VI Disease
Patients Present Normal Frequencies of
Circulating iNKT Cells
The frequency of iNKT cells is reduced in different mouse
models of LSD (16, 22, 25–30). The same was not observed
in NPC (31), Fabry (32), and Gaucher disease (33) patients’
blood. Here, we studied the percentage of total iNKT cells and
their CD4/CD8 phenotype in the blood of Gaucher, NPC, and
MPS-VI disease patients compared with control individuals and
our own published data on Fabry disease patients (32). No
significant differences were observed in the percentage of total
iNKT cells in Gaucher, NPC, and MPS-VI disease patients’ blood
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FIGURE 3 | CD1d-restricted lipid antigen presentation by Mo-DCs from Fabry, Gaucher, NPC and MPS-VI disease patients. Mo-DCs from Fabry (A), Gaucher (B),
NPC (C), and MPS-VI (D) disease patients and control subjects were loaded with 50 ng/mL of α-GalCer and co-cultured with the iNKT cell clone JS63. T cell
response was analyzed by measuring IL-4 or GM-CSF release to the supernatant by ELISA. Patients are represented with filled columns and control subjects with
open columns. Each column represents mean ± SD of duplicates for the same individual. Mo-DCs from Fabry (E) and Gaucher (F) disease patients and control
subjects were loaded with graded doses of sulfatide and co-cultured with the type II NKT cell clone s33d. T cell response was analyzed by measuring GM-CSF
release to the supernatant by ELISA. Patients are represented with filled symbols and control subjects with open symbols. Each symbol represents mean ± SD of
duplicates for the same individual at the indicated antigen concentration.
(Figure 6). However, when CD4/CD8 expression was analyzed,
Gaucher disease patients showed an increase in the percentage
of CD4+ and a decrease in the percentage of DN and CD8+
iNKT cells. NPC and MPS-VI disease patients did not present
significant alterations in the frequencies of CD4/CD8/DN iNKT
cells. Differences observed in Gaucher disease patients were
iNKT cell-specific, as total T cells and their subsets remained
unaltered (Supplementary Figure 1). Therefore, although Fabry
and Gaucher disease APCs showed no defects in their antigen
presentation capacity by CD1d, enzyme deficiency and their
consequences could impact the presence of certain iNKT cell
populations in the peripheral blood of these patients.
DISCUSSION
The lysosome has been described as an important intracellular
compartment for lipid antigen presentation, emphasized by
the defects observed in several mouse models of LSD (16,
25–29). However, the effects of lysosomal dysfunction present
in LSD patients on lipid antigen presentation by different
human CD1 molecules are unclear. Herein, we analyzed lipid
antigen presentation in patients affected by four different
LSDs, including three sphingolipidoses (Fabry, Gaucher, and
NPC) and one mucopolysaccharidosis (MPS-VI). We focused
on CD1b, as it is the human CD1 molecule that upon
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FIGURE 4 | CD1d-restricted lipid antigen presentation by monocytes from Fabry and Gaucher disease patients. Monocytes from Fabry (A) and Gaucher (B) disease
patients and control subjects were loaded with graded doses of α-GalCer (Fabry and Gaucher) or α-Gal-(1-2)-α-GalCer (Gaucher) and co-cultured with an iNKT cell
line. Patients are represented with filled symbols and control subjects with open symbols. Each symbol represents mean ± SD of duplicates for the same individual at
the indicated antigen concentration.
internalization recycles to the lysosome, and on CD1d,
to compare with the published data on mouse models
of LSD.
We found no major alterations in the capacity of APCs from
Fabry, Gaucher, NPC, and MPS-VI disease patients to present
exogenously added antigens that bind CD1b. The same was
observed for CD1d presentation of α-GalCer in the four studied
LSD. This is in contrast with what was observed for CD1d-
mediated lipid antigen presentation in mouse models of several
LSDs (16, 26–29). α-GalCer is a lipid whose internalization into
APCs is mediated by scavenger receptors (54) and is presented
by CD1d at the cell surface. Moreover, the loading of α-GalCer
onto CD1d is influenced by its access to a functional lysosomal
compartment in human APCs (55) and, in line with this notion,
several studies have described that APCs from mouse models of
LSD yield a decreased capacity to present α-GalCer (16, 26–29).
The capacity of Gaucher disease patients’ monocytes to
present α-Gal-(1-2)-αGalCer seems to be elevated, which is also
in contrast with the observation of a decreased capacity of APCs
from LSD mouse models to present α-Gal-(1-2)-αGalCer (16,
25–27), a lipid that needs to be internalized and cleaved by the
lysosomal α-Gal A enzyme to become antigenic.
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FIGURE 5 | CD1d lipid antigen presentation by in vitro cell models of Fabry
and Gaucher diseases. (A) Fabry disease in vitro cell model: CD1d-transfected
C1R cells were treated with DGJ 1mM + Gb3:BSA (filled columns) or
remained untreated (empty columns). (B) Gaucher disease in vitro cell model:
CD1d-transfected C1R cells were treated with CBE (filled columns) or
remained untreated (empty columns). Then, C1R cells were loaded with
50 ng/mL of α-GalCer and co-cultured with the iNKT cells clones JS63 or
VM-D5, or with an iNKT cell line. T cell response was analyzed by measuring
GM-CSF release to the supernatant by ELISA. Each column represents mean
± SD of duplicates. One representative experiment out of at least
two is shown.
In the NPC1 mouse model, lipid antigen trafficking to the
lysosome is compromised (27), which might explain the defects
in lipid antigen presentation. It would be interesting to address
if this impairment also occurs in APCs from LSD patients,
especially since lipid traffic in LSD patients’ fibroblasts was shown
to be altered (34).
In accordance with our results, a previous report has shown
that EBV transformed B cell lines from NPC patients, and
transfected with CD1d, have a normal capacity to present lipids
by this molecule (31). These apparent discrepancies between
mouse and human CD1d lipid antigen presentation in NPC and
Fabry diseases could be related to: (i) the described differences
in intracellular trafficking between human and mouse CD1d; (ii)
the discrepancy in lysosomal function between LSD patients and
mouse models; (iii) the different type of APC used in mouse and
human studies.
Mouse CD1d mainly recycles to the lysosome, contrary
to human CD1d which is usually found in late endocytic
compartments (56). In fact, when B cell lines from NPC patients
were transfected with mouse CD1d instead of human CD1d, a
decrease was observed in the APC capacity to present α-Gal-(1-
2)-αGalCer (31).
CD1bmediated antigen presentation was analyzed using GM1
and sulfatide, which are lipids that can bind to the cell surface
of CD1b (49, 57). GM1, due to its similarities to GM3, could
also require internalization via scavenger receptors in order to be
presented by CD1b (54). However, we must note that GM1 has
also been found to bind CD1b at the surface of fixed cells (49).
Interestingly, we observed that despite the lysosomal
alterations occurring in LSD patients, lipid presentation through
CD1b was not affected, allowing us to conclude that surface
CD1b in LSD APC is competent in presenting lipids. Therefore,
to draw more robust conclusions about CD1b-mediated lipid
antigen presentation, it would be useful to perform the same
type of studies with antigens that can only be presented by CD1b
upon internalization, like someMycobacterium lipids (6).
Another possible explanation for the differences found
between mice and humans is that while LSD animal models
correspond to full knock-outs of the gene, deficiencies in humans
may not translate into a full absence of the protein function.
It is also possible that partial restoration of enzymes or their
products with LSD treatments could be sufficient to compensate
for the potential impact on antigen presentation. However, in
the present study, blood (with the exception of NPC patients
who received oral daily substrate reduction therapy) was always
collected before infusion of the treatment (that was done
weekly or every 2 weeks) and dendritic cell differentiation from
monocytes takes more than 6 days in culture. It is therefore
unlikely that the recombinant enzyme used in the infusions
was present in considerable amounts in the Mo-DCs used in
the antigen presentation assays. Moreover, no difference in the
antigen presentation capacity was observed between treated and
non-treated patients.
Lipid antigen presentation defects observed in LSD mouse
models seem to be dependent on the nature of APC.
While splenocytes and thymocytes from GM1 gangliosidosis,
splenocytes from Sandhoff, or splenic DCs from Fabry disease
mice showed defects in α-GalCer presentation, bone marrow
derived DCs (BM-DCs) from the same mice were competent
in presenting this antigen to iNKT cells (26, 28, 29, 58). These
differences could be related to variable degrees of lipid storage
in distinct APCs or biological differences in antigen uptake or
presentation. It is known that fetal bovine serum used in culture
has a deficit in essential fatty acids, which results in an increased
lipogenesis by cells, leading to lipidomic modifications (59). This
could justify the absence of alterations observed when using
cells in culture, such as BM-DCs, Mo-DCs, or EBV-transformed
B cell lines. Having this in mind, we tested the capacity of
freshly isolated monocytes from Fabry and Gaucher patients
to present antigens by CD1d. No major defects were observed
in the presentation of the antigen α-GalCer, and monocytes
from Gaucher disease patients present a slightly higher capacity
to present α-Gal-(1-2)-αGalCer. Considering specifically Fabry
disease patients, the lack of major lipid antigen presentation
alterations can also be explained by the double effect of α-Gal A,
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FIGURE 6 | Frequencies of total iNKT cells and DN, CD4+, and CD8+ iNKT cells in Fabry, Gaucher, NPC, and MPS-VI disease patients. iNKT cells were identified in
PBMCs or CD14− fractions obtained from Fabry, Gaucher, NPC, and MPS-VI disease patients or control subjects, by their expression of CD3 and the recognition of
the CD1d-PBS57 tetramer. Antibodies against CD4 and CD8 were also used to define DN and positive subsets. Circles represent adults (≥16 years-old) and triangles
represent children (those under 16 years of age). Black circles identified adult patients that were not under treatment. All the pediatric patients were receiving
treatment. Horizontal line represents the mean of each group studied. Data normality was analyzed using the D’Agostino & Pearson normality test. To compare
patients with the control population, one-way ANOVA (for data with normal distribution) or Kruskal-Wallis test (data with non-normal distribution) were used. *p ≤ 0.05,
***p ≤ 0.001, ****p ≤ 0.0001.
the enzyme deficient in this disease. α-Gal A is known for its role
in the degradation of Gb3, a lipid that we recently demonstrated
to be inhibitory for iNKT cells (51). However, α-Gal A was also
implicated in the degradation of α-psychosine, an antigen that
was shown to be present in mammalian tissues (60). Thus, this
enzyme is responsible for the degradation of both antigenic (α-
psychosine) and inhibitory (Gb3) lipids for iNKT cells. Therefore,
it is plausible that α-Gal A deficiency leads to an increase in the
cellular content of both lipids, thus maintaining their ratio and
preventing major alterations in iNKT cell activation.
In our study, we also found a variable response of T cell
clones to Mo-DCs and monocytes from different subjects,
which does not seem to be related to age or gender. CD1
genes display a limited polymorphism but some substitutions
have been described for exon 2 (61), although the impact
of these substitutions in lipid antigen presentation is not
clear. Nevertheless, studies in mice have revealed that CD1d
polymorphisms affect antigen presentation and activation of
CD1d-restricted T cells (62, 63), suggesting that the same may
happen in humans.
The percentage of total iNKT cells was found unaltered in
the peripheral blood of Fabry (32), Gaucher, NPC, and MPS-VI
disease patients. However, as described before for Fabry disease
patients (32), an alteration in the frequency of CD4/CD8/DN
iNKT cells was observed in Gaucher disease patients, showing a
significant increase of the CD4+ population and a decrease of DN
and CD8+ iNKT cells. These results suggest a higher egress of
CD4+ iNKT cells from the thymus of Gaucher patients, which
can be related with a propitious cytokine environment for the
selection of this subset or an alteration in the antigen availability
that could potentiate their selection. Finally, a difference in the
frequency of iNKT cells in other localizations than blood cannot
be excluded.
In conclusion, we show that APCs from Fabry, Gaucher, NPC,
andMPS-VI disease patients are capable of presenting exogenous
lipid antigens that bind CD1b and CD1d. In the future, for CD1b,
it will be important to extend the study to lipid antigens that
require internalization. It will be also interesting to elucidate
whether lipid imbalances and other cellular alterations present
in LSD will affect CD1 mediated self-lipid antigen presentation.
Moreover, deciphering the factors favoring the thymic selection
of CD4+ iNKT cells or inhibiting the proliferation of CD4−
iNKT cells in the periphery of Gaucher patients would also
be relevant.
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Supplementary Figure 1 | Frequencies of total CD3+ T cells and their CD4+
and CD8+ subsets in Fabry, Gaucher, NPC and MPS-VI disease patients. Total T
cells were identified, in PBMCs or CD14− fractions obtained from Fabry, Gaucher,
NPC and MPS-VI disease patients or control subjects, by their expression of CD3.
Antibodies against CD4 and CD8 were also used to define positive subsets.
Circles represent adults (over 16 years of age) and triangles children (under 16
years of age). Black circles identify adult patients that were not under treatment.
All the pediatric patients were receiving treatment. Horizontal line represents the
mean of each group studied. Normality of each group was analyzed using the
D’Agostino & Pearson normality test. To compare patients with the control
population, one-way ANOVA (for data with normal distribution) or Kruskal-Wallis
test (data with non-normal distribution) were used. ∗∗p ≤ 0.01.
Supplementary Figure 2 | Determination of T cell purity. DS1C9b, GG33A, and
s33d T cells purity was analyzed by using the anti-human TCR Vβ7.1, Vβ18, and
Vβ13.1 monoclonal antibodies, respectively. iNKT cells were analyzed for CD1d
PBS57 tetramer reactivity. The unstained control is represented in gray.
Supplementary Figure 3 | Statistical analysis of CD1b-restricted lipid antigen
presentation by Mo-DCs. (A) Mo-DCs from Fabry, Gaucher, NPC, and MPS-VI
disease patients and control subjects were loaded with 5µg/mL of GM1 and
co-cultured with the CD1b-restricted T cell clone GG33A. (B) Mo-DCs from Fabry
and NPC disease patients and control subjects were loaded with 1µg/mL or
5µg/mL of sulfatide and co-cultured with the CD1b-restricted T cell clone
DS1C9b. The graphs on the left correspond to the cytokine production values.
The graphs on the right correspond to the normalized values. Normalization was
done for each independent assay considering the highest cytokine production
value as 100. Patients are represented with filled symbols and control subjects
with open symbols. Each symbol represents the mean of duplicates for the same
condition. An unpaired t-test (normal distribution) or a Mann-Whitney test
(non-normal distribution) was used to compare both groups. P-values lower than
0.05 were considered significant. ∗p ≤ 0.05, ∗∗p ≤ 0.01. The graphs with no
symbols relative to statistical analysis means that there were no statistically
significant differences.
Supplementary Figure 4 | Lipid accumulation in in vitro cell models of Fabry and
Gaucher diseases. (A) Fabry disease in vitro cell model: C1R cells treated with
DGJ 1mM, DGJ 1mM + Gb3:BSA or untreated cells were lysed by sonication.
Lipids were extracted and fractioned. The neutral fraction was analyzed by TLC
and the Gb3 band intensity was quantified and divided by Sph/Gb4 intensity.
(B) Gaucher disease in vitro cell model: C1R cells treated with CBE 1mM or
untreated cells were lysed by sonication. Lipids were extracted, fractioned and the
neutral fraction was analyzed by TLC. GlcCer band intensity was quantified and
divided by Sph/Gb4 intensity. GlcCer, glucosylceramide; PE,
phosphatidylethanolamine; LacCer, lactosylceramide; Gb3, globotriaosylceramide;
Sph, sphingomyelin; Gb4, Globotetraosylceramide; Cer4, ganglioside GM1.
Supplementary Figure 5 | Basal production of GM-CSF by (A) Mo-DCs and (B)
monocytes. Mo-DCs or monocytes from Gaucher (G) disease patients, MPS VI (M)
disease patient and control (C) subjects were loaded with 50 ng/mL of α-GalCer
(GC) or 300 ng/mL of α-Gal-(1-2)-α-GalCer (GGC) and co-cultured or not with an
iNKT cell line. After 40 h, GM-CSF was measured in the culture supernatants.
Each bar represents mean ± SD of duplicates for the same condition.
Supplementary Figure 6 | Statistical analysis of CD1d-restricted lipid antigen
presentation by Mo-DCs. (A) Mo-DCs from Fabry, Gaucher, NPC, and MPS-VI
disease patients and control subjects were loaded with 50 ng/mL of α-GalCer and
co-cultured with the iNKT cell clone JS63. (B) Mo-DCs from Fabry and Gaucher
disease patients and control subjects were loaded with 10µg/mL of sulfatide and
co-cultured with the type II NKT cell clone s33d. The graphs on the left
correspond to the cytokine production values. The graphs on the right correspond
to the normalized values. The normalization was done for each independent assay
considering the highest cytokine production value as 100. Patients are
represented with filled symbols and control subjects with open symbols. Each
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symbol represents mean of duplicates for the same condition. An unpaired t-test
(normal distribution) or a Mann-Whitney test (non-normal distribution) was used to
compare both groups. P-values lower than 0.05 were considered significant. The
graphs with no symbols relative to statistical analysis means that there were no
statistically significant differences.
Supplementary Figure 7 | Statistical analysis of CD1d-restricted lipid antigen
presentation by monocytes. Monocytes from Fabry and Gaucher disease patients
and control subjects were loaded with 50 ng/mL of α-GalCer or 50 ng/mL of
α-Gal-(1-2)-α-GalCer and co-cultured with an iNKT cell line. The graphs on the left
correspond to the cytokine production values. The graphs on the right correspond
to the normalized values. The normalization was done for each independent assay
considering the highest cytokine production value as 100. Patients are
represented with filled symbols and control subjects with open symbols. Each
symbol represents the mean of duplicates for the same condition. An unpaired
t-test (normal distribution) or a Mann-Whitney test (non-normal distribution) was
used to compare both groups. P-values lower than 0.05 were considered
significant. ∗∗p ≤ 0.01. The graphs with no symbols relative to statistical analysis
means that there were no statistically significant differences.
Supplementary Table 1 | CD1b, CD1d, and CD80 expression∗ on Mo-DCs from
LSD patients.
Supplementary Table 2 | CD1d, and CD80 expression∗ on Monocytes from LSD
patients.
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